WASHINGTON — Elizabeth Jungman, a well-known public health expert and a Capitol Hill veteran, will lead the FDA’s regulatory policy office starting this summer, STAT has learned.

Jungman, who currently serves as head of public health programs at the Pew Charitable Trusts, will direct the FDA’s Office of Regulatory Policy, a post within the FDA’s Center for Drug Evaluation and Research with sweeping authority over FDA’s human drugs portfolio, two sources told STAT. The office is perhaps most known for its role in regulating drug compounding, although it has also led some of the FDA’s work on other hot-button issues like abuses of the agency’s safety systems and its regulation of homeopathic drugs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy